1
|
Carmona-Rivera C, Kaplan MJ, O'Neil LJ. Neutrophils in Inflammatory Bone Diseases. Curr Osteoporos Rep 2024; 22:280-289. [PMID: 38418800 PMCID: PMC11061041 DOI: 10.1007/s11914-024-00865-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 02/16/2024] [Indexed: 03/02/2024]
Abstract
PURPOSE OF REVIEW In this review, we summarize the current evidence that suggests that neutrophils play a key role in facilitating damage to local bone structures. RECENT FINDINGS Neutrophil infiltration is a hallmark of inflammatory bone diseases such as rheumatoid arthritis (RA) and periodontitis disease (PD). Both of these human diseases are marked by an imbalance in bone homeostasis, favoring the degradation of local bone which ultimately leads to erosions. Osteoclasts, a multinucleated resident bone cell, are responsible for facilitating the turnover of bone and the bone damage observed in these diseases. The involvement of neutrophils and neutrophil extracellular trap formation have recently been implicated in exacerbating osteoclast function through direct and indirect mechanisms. We highlight a recent finding that NET proteins such as histones and elastase can generate non-canonical, inflammatory osteoclasts, and this process is mediated by post-translational modifications such as citrullination and carbamylation, both of which act as autoantigens in RA. It appears that NETs, autoantibodies, modified proteins, cytokines, and osteoclasts all ultimately contribute to local and permanent bone damage in RA and PD. However, more studies are needed to fully understand the role of neutrophils in inflammatory bone diseases.
Collapse
Affiliation(s)
- Carmelo Carmona-Rivera
- Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
| | - Mariana J Kaplan
- Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Liam J O'Neil
- Manitoba Centre for Proteomics and Systems Biology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
| |
Collapse
|
2
|
Zappia J, Tong Q, Van der Cruyssen R, Cornelis FMF, Lambert C, Pinto Coelho T, Grisart J, Kague E, Lories RJ, Muller M, Elewaut D, Hammond CL, Sanchez C, Henrotin Y. Osteomodulin downregulation is associated with osteoarthritis development. Bone Res 2023; 11:49. [PMID: 37730805 PMCID: PMC10511717 DOI: 10.1038/s41413-023-00286-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 07/17/2023] [Accepted: 08/12/2023] [Indexed: 09/22/2023] Open
Abstract
Abnormal subchondral bone remodeling leading to sclerosis is a main feature of osteoarthritis (OA), and osteomodulin (OMD), a proteoglycan involved in extracellular matrix mineralization, is associated with the sclerotic phenotype. However, the functions of OMD remain poorly understood, specifically in vivo. We used Omd knockout and overexpressing male mice and mutant zebrafish to study its roles in bone and cartilage metabolism and in the development of OA. The expression of Omd is deeply correlated with bone and cartilage microarchitectures affecting the bone volume and the onset of subchondral bone sclerosis and spontaneous cartilage lesions. Mechanistically, OMD binds to RANKL and inhibits osteoclastogenesis, thus controlling the balance of bone remodeling. In conclusion, OMD is a key factor in subchondral bone sclerosis associated with OA. It participates in bone and cartilage homeostasis by acting on the regulation of osteoclastogenesis. Targeting OMD may be a promising new and personalized approach for OA.
Collapse
Affiliation(s)
- Jérémie Zappia
- MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, Belgium.
| | - Qiao Tong
- School of Physiology, Pharmacology, and Neuroscience, University of Bristol, Bristol, UK
| | - Renée Van der Cruyssen
- Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
- Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
| | - Frederique M F Cornelis
- Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
| | - Cécile Lambert
- MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, Belgium
| | - Tiago Pinto Coelho
- Cardiovascular Sciences, Groupe Interdisciplinaire de Génoprotéomique Appliquée, Université de Liège, Liège, Belgium
- Division of Nephrology, CHU of Liège, Université de Liège, Liège, Belgium
| | | | - Erika Kague
- School of Physiology, Pharmacology, and Neuroscience, University of Bristol, Bristol, UK
| | - Rik J Lories
- Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
- Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium
| | - Marc Muller
- Laboratoire d'Organogenèse et Régénération, Groupe Interdisciplinaire de Génoprotéomique Appliquée, Université de Liège, Liège, Belgium
| | - Dirk Elewaut
- Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
- Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
| | - Chrissy L Hammond
- School of Physiology, Pharmacology, and Neuroscience, University of Bristol, Bristol, UK
| | - Christelle Sanchez
- MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, Belgium
| | - Yves Henrotin
- MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, Belgium
- Artialis SA, Tour GIGA, CHU Sart-Tilman, Liège, Belgium
- Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium
| |
Collapse
|